Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.